CVS Caremark Corporation agreed to pay 5 million to settle Federal Trade Commission charges that it misrepresented the prices of certain Medicare Part D prescription drugs -- including drugs used to treat breast cancer symptoms and epilepsy -- at CVS and Walgreens pharmacies. The allegedly deceptive claims caused many seniors and disabled consumers to pay significantly more for their drugs than they expected and pushed them into the "donut hole,"  a term referring to the coverage gap where none of their drug costs are reimbursed  sooner than they anticipated or planned. The settlement barred deceptive claims related to Medicare Part D drug prices and required CVS Caremark to pay 5 million to reimburse affected Medicare Part D consumers for the price discrepancy.

6817

Discover more like this

6817

Description

Traits

Contract details

Provenance

Discover more like this